CureVac (NASDAQ:CVAC) Trading Up 9.1% – Still a Buy?

CureVac (NASDAQ:CVAC) shares rose 9.1% during trading on Tuesday . The company traded as high as $3.12 and last traded at $3.19. Approximately 481,439 shares changed hands during mid-day trading, a decline of 46% from the average daily volume of 885,243 shares. The stock had previously closed at $2.92.

Analyst Ratings Changes

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $16.00 price objective on shares of CureVac in a research report on Friday, February 14th.

CureVac Price Performance

The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. The company has a market cap of $707.46 million, a P/E ratio of 5.75 and a beta of 2.53. The firm’s fifty day moving average is $3.66 and its two-hundred day moving average is $3.20.

Hedge Funds Weigh In On CureVac

A number of hedge funds have recently made changes to their positions in the business. Barclays PLC purchased a new stake in CureVac during the 3rd quarter valued at approximately $67,000. Public Employees Retirement System of Ohio bought a new position in shares of CureVac during the 3rd quarter valued at about $91,000. Jane Street Group LLC grew its position in shares of CureVac by 239.0% during the third quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock valued at $235,000 after purchasing an additional 55,867 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of CureVac by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company’s stock worth $162,000 after purchasing an additional 4,425 shares during the last quarter. Finally, Integrated Wealth Concepts LLC bought a new position in CureVac during the third quarter valued at approximately $35,000. Institutional investors own 17.26% of the company’s stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.